Michael Jeltsch

Prof. Dr. Michael Jeltsch

Drug Research Program, Faculty of Pharmacy, University of Helsinki, Finland
+2
orcid

Biography

Moved from Germany to Finland in 1995 — Ph.D. in 2003 with Kari Alitalo: Discovery of the first growth factors for lymphatic vessels: VEGF-C and VEGF-D — Since 2013 group leader and since 2020 Associate Professor in Pharmaceutical Protein Drug Research at the Faculty of Pharmacy (University of Helsinki) — Research interests: Vascular biology, biological drugs, antibody technologies, protein design — Experience in three biotech startups with several patents and 3 drugs in clinical trials: OPT-302 (developer), VGX-100 and Lymfactin (co-developer) — More at jeltsch.org (private) or mjlab.fi (lab)

Affiliations

No affiliation has been shared yet.

Honors and Awards

honor

Best Basic Science Paper of 2014

American Heart Association/Circulation

For discovering the molecular etiology of Hennekam Syndrome, a hereditary condition characterized by generalized lymphedema (i.e discovering the function of CCBE1 and ADAMTS3 as the primary activating protease of VEGF-C); published in Circulation

honor

Medix Prize 1998, 2004, 2011

Minerva Foundation

For the best biomedical publication of the year in Finland: Tvorogov 2011, Cancer Cell; Kärkkäinen 2004, Nat Im­munol; Jeltsch 1998, Science.

Experience

No experience has been shared yet.